Results 31 to 40 of about 108,215 (260)

Post-CAR-T cell therapy presenting as proteinaceous lymphadenopathy

Human Pathology: Case Reports, 2021
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma and is often treated with chemotherapy, autologous stem cell transplant, and chimeric antigen receptor (CAR-T) cell therapy.
Mishi Bhushan, Kirthi R. Kumar
doaj   +1 more source

Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma

Haematologica, 2012
Background FoxM1 has been shown to play a critical role in the pathogenesis of various epithelial malignancies. However, its role in lymphoid malignancies has not been fully clarified.
Shahab Uddin, Azhar R Hussain, Maqbool Ahmed, Khawar Siddiqui, Fouad Al-Dayel, Prashant Bavi, Khawla S. Al-Kuraya   +6 more
doaj   +1 more source

Concurrent myasthenia gravis-related cervical thymoma in a patient with diffuse large B-cell lymphoma: a case report

Journal of Medical Case Reports, 2022
Background Cervical thymoma is a rare thymic epithelial neoplasm. Evidence supports an increased risk of second primary malignancies in patients with thymoma.
Chutima Kunacheewa, Sattawut Wongwiangjunt, Sanya Sukpanichnant   +2 more
doaj   +1 more source

Derepressing of STAT3 and USP7 contributes to resistance of DLBCL to EZH2 inhibition

Heliyon, 2023
Diffuse large B-cell lymphoma is the most common subtype of lymphoma, representing ∼25 % of non-Hodgkin lymphoid malignancies. EZH2 is highly expressed in Diffuse large B-cell lymphoma and ∼22 % of patients contain EZH2 mutations.
Chenyun He, Wenbin Zhou, Xiaoxia Jin, Haining Zhou   +3 more
doaj   +1 more source

SnapShot: Diffuse Large B Cell Lymphoma

Cancer Cell, 2014
Diffuse large B cell lymphoma (DLBCL) is the most prevalent non-Hodgkin lymphoma (NHL) in adulthood, comprising 30%–40% of all new diagnoses. This aggressive disease can arise de novo or, less frequently, from the clinical evolution of various indolent B cell malignancies. While durable remissions can be achieved in a substantial proportion of cases by
PASQUALUCCI, Laura, Dalla Favera R.
openaire   +3 more sources

The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells

Haematologica, 2017
The forkhead transcription factor FOXP1 is generally regarded as an oncogene in activated B cell-like diffuse large B-cell lymphoma. Previous studies have suggested that a small isoform of FOXP1 rather than full-length FOXP1, may possess this oncogenic ...
Martine van Keimpema, Leonie J. Grüneberg, Esther J.M. Schilder-Tol, Monique E.C.M. Oud, Esther A. Beuling, Paul J. Hensbergen, Johann de Jong, Steven T. Pals, Marcel Spaargaren   +8 more
doaj   +1 more source

Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas

Haematologica, 2008
Background Follicular lymphomas are currently subdivided into grades I, II, IIIa and IIIb. This distinction is, however, questioned.Design and Methods We studied the gene expression profile of 43 follicular lymphomas, 50 B-cell non-Hodgkin’s lymphomas of
Pier Paolo Piccaluga, Andrea Califano, Ulf Klein, Claudio Agostinelli, Beatriz Bellosillo, Eva Gimeno, Sergi Serrano, Francisco Solè, Yonghui Zang, Brunangelo Falini, Pier Luigi Zinzani, Stefano A. Pileri   +11 more
doaj   +1 more source

Retrospective Analysis of Pemetrexed-based Chemotherapy Regimens on Mid-elderly Non-Hodgkin's Lymphoma

Zhongliu Fangzhi Yanjiu, 2020
Objective To analyze the safety and efficacy of pemetrexed-based chemotherapy on patients with mid-elderly non-Hodgkin's lymphoma. Methods We retrospectively reviewed the clinical data of patients with non-Hodgkin's lymphoma treated with pemetrexed-based
WEN Tingyu, GUI Lin, JIN Jun, ZHANG Wei, WANG Ting, SHI Yuankai, LIU Peng   +6 more
doaj   +1 more source

Non-Hodgkin’s Lymphoma in Buccal Vestibule -Case Report [PDF]

Journal of Clinical and Diagnostic Research, 2014
Lymphomas are malignant neoplasms arising from lymphocytes B cell or T cell that affects mainly lymph nodes, spleen and other non hematopoietic tissues. They are classified as Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). Diffuse large B-cell
Indira Reddy, Sreenath G, Raghavendra Readdy Y, Ravi Prakash .A, Swathi T R   +4 more
doaj   +1 more source

Genomics of diffuse large B cell lymphoma

BLOOD RESEARCH, 2021
Next generation sequencing (NGS) technology has revealed the heterogeneity of diffuse large B-cell lymphoma (DLBCL) from a mutation perspective. Accordingly, the conventional cell of origin-based classification of DLBCL has changed to a mutation-based classification.
openaire   +3 more sources